The acute or chronic drug treatments for different neurodegenerative and psychiatric
disorders are challenging from several aspects. The low bioavailability and limited brain …

The blood–brain barrier (BBB) has shown to be a significant obstacle to brain medication
delivery. The BBB in a healthy brain is a diffusion barrier that prevents most substances from …

Astrocytes have important roles in the central nervous system (CNS) during health and
disease. Through genome-wide analyses we detected a transcriptional response to type I …

Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disorder of the central
nervous system (CNS). Current therapies mainly target inflammatory processes during acute …

Central nervous system (CNS) disorders (eg, multiple sclerosis, Alzheimer's disease, etc.)
represent a growing public health issue, primarily due to the increased life expectancy and …

Treatment of central nervous system (CNS) diseases is very difficult due to the blood–brain
barrier's (BBB) ability to severely restrict entry of all but small, non-polar compounds …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system associated
with demyelination and axonal loss eventually leading to neurodegeneration. MS exhibits …

There has been an unprecedented interest in the modulatory effects of intranasal oxytocin
on human social cognition and behaviour, however as yet no study has actually …

The blood–brain barrier (BBB) limits the distribution of systemically administered
therapeutics to the central nervous system (CNS), posing a significant challenge to drug …

Introduction: The blood–brain barrier (BBB) represents a stringent barrier for delivery of
neurotherapeutics in vivo. An attempt to overcome this barrier is represented by the direct …